Testing effectiveness (Phase 2)Active Not RecruitingNCT05406401
What this trial is testing
Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Who this might be right for
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Merck Sharp & Dohme LLC 60